Table 4 Recombinant MeV vaccines targeting diseases transmitted by fluids or sexual contact.

From: Versatility of live-attenuated measles viruses as platform technology for recombinant vaccines

Target

Antigen

ATUa

Strainb

IFNAR−/− c

CD46-miced

hum. Micee

Cotton rats

Rhesus mac.

Cynomolgus

ELISAf

nAbsg

ELISpoth

ICSi

Challengej

Clinical trial

Refs.

EBV

gB350

N, P

Edm-Zagreb

   

X

X

 

X

neg

X

   

41

HBV

HBsAg

P

Edm-B

 

X

    

X

     

30

HBsAg

N, P, H, L

Moraten

 

X

  

X

 

X

   

MeV

 

28,69

HCV

E1, E2

N

Edm-B

  

X

   

X

     

70

C, E1, E2; E1/Ft, E2/Ft

P

Moraten

 

X

    

X

X

    

71

Helicobacter pylori

NAP

pre-N

Edm-B

X

X

    

X

 

X

   

84

HIV-1

Env

P, H

Edm-B

 

X

  

X

 

X

X

X

X

 

I

82

Env

P

Schwarz

 

X

    

X

X

 

X

 

83

Gag +

Env

P

H

Schwarz

 

X

    

X

X

X

  

76

Env,

Gag + Pol;

Gag

P

P, H;

P

Moraten

 

X

    

X

 

X

  

75

F4

P

Schwarz

 

X

   

X

X

  

X

 

79,80,81

HPV

L1

P

Edm-Zagreb

 

X

  

X

 

X

X

    

72,73

SHIV

Gag, Env;

Nef

P, H;

pre-N

Schwarz

     

X

X

X

X

X

X

 

78

SIVmac

Env; Pol; Gag

P, H; P; H

Edm-B

            

50

Env (+ Pol); Gag

P; H

Edm-B

 

X

    

X

     

74

Gag

P

Edm-Zagreb

    

X

 

X

 

X

X

  

77

  1. Listed are all MeV-derived experimental vaccines that target diseases transmitted by fluids or sexual contact. Described are the vaccine properties; depicted by “X” are the animal model(s) those have been tested in, positive immune responses detected in those models directed against the additional antigen(s), and efficacy in animal challenge models or clinical trials. Negative results in performed assays are labeled with neg. aGenomic position of the additional transcription unit (ATU); pre-N indicates first position in the genome, N, P, H, or L indicate position of the ATU directly following N, P, H, or L gene cassettes, respectively. bVaccine strain, the backbone of respective recombinant MeV has been derived from. c–ePreclinical or clinical model organism to analyze induction of immunity; cIFNAR−/−: mice with defect in innate Type I IFN responsiveness; dCD46-mice: Mice transgenic for MeV vaccine strain receptor CD46 and defect in innate Type I IFN responsiveness; ehum. mice: humanized mice - NOD/Scid/Jak3null mice engrafted with human peripheral blood leukocytes (hu-PBL-NOJ). f–iAntigen-specific immune responses triggered after immunization, which has been determined by fmeasuring total antibodies (ELISA), gneutralizing antibodies (nAbs), or reactive T cells determined by hELISpot or iintracellular cytokine staining (ICS). jProtective capacity of vaccine-induced immune responses after challenge of the appropriate animal model determined by reduction of pathogen load or attenuation of etiopathology.